Skip to main content
Erschienen in: Pathology & Oncology Research 2/2015

01.04.2015 | Research

Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China

verfasst von: Qiancheng Hu, Ting Luo, Ping He, Xiaorong Zhong, Tinglun Tian, Qing Lv, Xi Yan, Hong Zheng

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

To analyze the changing patterns of treatment and to explore the current treatment approaches for breast cancer in Southwest China, we conducted a population-based retrospective cohort study of early breast cancer cases. The data of patients who registered in the information management system for breast cancer in Huaxi Hospital, Sichuan University from 1989 to 2012 were extracted. Nearly all patients underwent surgery, among whom radical mastectomy was the predominant option. Chemotherapy (88.7 %) was the most predominant adjuvant therapy approach. The percentage of patients receiving radiation therapy displayed fluctuant increase, which was 37.1 % in 2001 and reached up to 67.6 % in 2011. Besides, the endocrinetherapy became more and more popular in the hormone-receptor positive patients and the percentage of endocrinetherapy was increased from 54.1 at 2001 to 85.6 % at 2011. However, more than 10 % of hormone-receptor positive patients still did not receive endocrinetherapy annually. The hormone-receptor positive patients who received endocrinetherapy had better 5-year disease free survival (DFS) and overall survival (OS) compared to those without endocrinetherapy (5-y DFS: 88.4 % vs. 75.1 %, P < 0.001; 5-y OS: 95.7 % vs. 88.4 %, P < 0.001). N stage appeared to have greater impact on the 5-year DFS and OS than molecular subtyping. The treatment for breast cancer in China has been significantly improved but more attentions should be paid to radiotherapy and endocrine therapy. In addition, the value of N stage in the prognosis of breast cancer should not be ignored when the molecular typing draws more and more attentions.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed
2.
Zurück zum Zitat Huang X-E, Hirose K, Wakai K et al (2004) Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev 5:419–427PubMed Huang X-E, Hirose K, Wakai K et al (2004) Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev 5:419–427PubMed
3.
Zurück zum Zitat Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907CrossRefPubMed Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907CrossRefPubMed
4.
Zurück zum Zitat Fan L, Zheng Y, Yu KD et al (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409–416CrossRefPubMed Fan L, Zheng Y, Yu KD et al (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409–416CrossRefPubMed
5.
Zurück zum Zitat Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792CrossRefPubMed Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792CrossRefPubMed
6.
Zurück zum Zitat Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRefPubMed Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRefPubMed
7.
Zurück zum Zitat Ctsu RI (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Ctsu RI (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
8.
Zurück zum Zitat Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed
9.
Zurück zum Zitat Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed
10.
Zurück zum Zitat Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRefPubMed Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRefPubMed
11.
Zurück zum Zitat Eggemann H, Ignatov A, Smith BJ et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470CrossRefPubMed Eggemann H, Ignatov A, Smith BJ et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470CrossRefPubMed
12.
Zurück zum Zitat Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373CrossRefPubMedCentralPubMed Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Welslau M, Dieras V, Sohn JH et al (2014) Patient-reported outcomes from EMILIA, a randomized phase 3 study of Trastuzumab Emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer-Am Cancer Soc 120:642–651 Welslau M, Dieras V, Sohn JH et al (2014) Patient-reported outcomes from EMILIA, a randomized phase 3 study of Trastuzumab Emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer-Am Cancer Soc 120:642–651
14.
Zurück zum Zitat Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445CrossRefPubMed Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445CrossRefPubMed
15.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608CrossRefPubMed Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608CrossRefPubMed
16.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19:3817–3827PubMed Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19:3817–3827PubMed
17.
Zurück zum Zitat Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365CrossRefPubMed Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365CrossRefPubMed
18.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583CrossRefPubMed Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583CrossRefPubMed
19.
Zurück zum Zitat Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329CrossRefPubMedCentralPubMed Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72PubMed Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72PubMed
21.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedCentralPubMed Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Network NCC, NCCN clinical practice guidelines in oncology: breast cancer (2007) National comprehensive cancer network Network NCC, NCCN clinical practice guidelines in oncology: breast cancer (2007) National comprehensive cancer network
23.
Zurück zum Zitat Harbeck N, Jakesz R (2007) St. Gallen 2007: breast cancer treatment consensus report. Breast Care 2:130–134CrossRef Harbeck N, Jakesz R (2007) St. Gallen 2007: breast cancer treatment consensus report. Breast Care 2:130–134CrossRef
24.
Zurück zum Zitat Parkin DM, Fernández LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12:S70–S80CrossRefPubMed Parkin DM, Fernández LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12:S70–S80CrossRefPubMed
25.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502CrossRefPubMed Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502CrossRefPubMed
26.
Zurück zum Zitat Xue C, Wang X, Peng R et al (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 103:1679–1687CrossRefPubMedCentralPubMed Xue C, Wang X, Peng R et al (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 103:1679–1687CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874CrossRefPubMedCentralPubMed Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Kurebayashi J, Moriya T, Ishida T et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. The Breast 16:72–77CrossRef Kurebayashi J, Moriya T, Ishida T et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. The Breast 16:72–77CrossRef
29.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer 109:1721–1728CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer 109:1721–1728CrossRefPubMed
30.
Zurück zum Zitat Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed
31.
Zurück zum Zitat Zhao J, Liu H, Wang M et al (2009) Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Clin Oncol 100:89–94 Zhao J, Liu H, Wang M et al (2009) Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Clin Oncol 100:89–94
32.
Zurück zum Zitat Panjwani P, Epari S, Karpate A et al. (2010) Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India Panjwani P, Epari S, Karpate A et al. (2010) Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India
33.
Zurück zum Zitat Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607CrossRefPubMed Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607CrossRefPubMed
34.
Zurück zum Zitat Yu K-D, Li S, Shao Z-M (2011) Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery. Oncologist 16:1101–1110CrossRefPubMedCentralPubMed Yu K-D, Li S, Shao Z-M (2011) Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery. Oncologist 16:1101–1110CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Smith GL, Xu Y, Shih Y-CT et al (2009) Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 209:425–433. e422CrossRefPubMed Smith GL, Xu Y, Shih Y-CT et al (2009) Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 209:425–433. e422CrossRefPubMed
36.
Zurück zum Zitat Li J, Zhang B-N, Fan J-H et al (2011) A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer 11:364CrossRefPubMedCentralPubMed Li J, Zhang B-N, Fan J-H et al (2011) A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer 11:364CrossRefPubMedCentralPubMed
38.
Zurück zum Zitat Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537CrossRefPubMedCentralPubMed Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537CrossRefPubMedCentralPubMed
39.
Zurück zum Zitat Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109:832–839CrossRefPubMed Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109:832–839CrossRefPubMed
40.
Zurück zum Zitat Baum M, Budzar A, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMed Baum M, Budzar A, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMed
41.
Zurück zum Zitat Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMed Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMed
42.
Zurück zum Zitat Dixon JM, Jackson J, Hills M et al (2004) Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 40:2742–2747CrossRefPubMed Dixon JM, Jackson J, Hills M et al (2004) Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 40:2742–2747CrossRefPubMed
43.
Zurück zum Zitat Ihemelandu CU, Leffall LD Jr, Dewitty RL et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Oncol 143:109–118 Ihemelandu CU, Leffall LD Jr, Dewitty RL et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Oncol 143:109–118
44.
Zurück zum Zitat Wang GS, Zhu H, Bi SJ (2012) Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Report 6:779–782 Wang GS, Zhu H, Bi SJ (2012) Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Report 6:779–782
Metadaten
Titel
Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China
verfasst von
Qiancheng Hu
Ting Luo
Ping He
Xiaorong Zhong
Tinglun Tian
Qing Lv
Xi Yan
Hong Zheng
Publikationsdatum
01.04.2015
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2015
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9829-z

Weitere Artikel der Ausgabe 2/2015

Pathology & Oncology Research 2/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.